<DOC>
	<DOC>NCT00688545</DOC>
	<brief_summary>This multi-center observational Registry will collect long-term safety data on patients treated with celecoxib or non-selective nonsteroidal anti-inflammatory drugs (nsNSAIDs) as used in clinical practice for the treatment of Juvenile Idiopathic Arthritis (JIA).</brief_summary>
	<brief_title>Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis</brief_title>
	<detailed_description>None Study has been terminated early (LSLV = 09Jan2012) due to release of the postmarketing commitment by the US FDA. The study was stopped for futility/change in treatment paradigm that minimizes chronic NSAID use and not for safety concerns.</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Juvenile</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Age at least 2 years but less than 18 years; JIA of any of the following subtypes: oligoarthritis, polyarthritis, or stable systemic disease; new treatment (started not more than 6 months prior) with one NSAID (celecoxib or nsNSAID). Patients with the following JIA subtypes: active systemic disease, psoriatic Arthritis, enthesitisrelated Arthritis, or undifferentiated arthritis; Patients with Reiter's syndrome; patients unlikely to complete 2 years of follow up; Patients who need to use multiple NSAIDs at the same time.</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Celecoxib</keyword>
	<keyword>COX-2</keyword>
	<keyword>NSAIDs</keyword>
	<keyword>observational study</keyword>
	<keyword>noninterventional study</keyword>
	<keyword>cohort study</keyword>
	<keyword>registry</keyword>
	<keyword>epidemiologic study</keyword>
	<keyword>pediatrics</keyword>
	<keyword>rheumatology</keyword>
	<keyword>phase iv study</keyword>
</DOC>